DRNA Dicerna Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

DRNA [NASD]

Dicerna Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.69	Insider Own	0.10%	Shs Outstand	72.92M	Perf Week	-3.04%
Market Cap	1.91B	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-72.84%	Shs Float	68.46M	Perf Month	19.03%
Income	-116.80M	PEG	-	EPS next Q	0.10	Inst Own	86.90%	Short Float	4.33%	Perf Quarter	27.18%
Sales	54.80M	P/S	34.81	EPS this Y	-10.20%	Inst Trans	6.40%	Short Ratio	4.34	Perf Half Y	12.04%
Book/sh	2.44	P/B	10.20	EPS next Y	-420.00%	ROA	-22.50%	Target Price	33.78	Perf Year	74.06%
Cash/sh	9.22	P/C	2.70	EPS next 5Y	-	ROE	-74.80%	52W Range	11.75 - 27.68	Perf YTD	12.98%
Dividend	-	P/FCF	7.86	EPS past 5Y	10.10%	ROI	-84.20%	52W High	-10.08%	Beta	1.83
Dividend %	-	Quick Ratio	2.90	Sales past 5Y	-	Gross Margin	-	52W Low	111.83%	ATR	1.29
Employees	187	Current Ratio	2.90	Sales Q/Q	996.80%	Oper. Margin	-	RSI (14)	53.38	Volatility	3.72% 6.08%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	19.50%	Profit Margin	-	Rel Volume	0.45	Prev Close	25.39
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	682.95K	Price	24.89
Recom	1.60	SMA20	2.67%	SMA50	10.05%	SMA200	22.06%	Volume	304,080	Change	-1.97%

May-13-20

Initiated

RBC Capital Mkts

Outperform

$35

Mar-19-20

Initiated

Berenberg

Buy

$35

Nov-19-19

Reiterated

H.C. Wainwright

Buy

$22 → $30

Oct-29-19

Initiated

Robert W. Baird

Outperform

May-24-19

Resumed

Citigroup

Buy

$30

Jan-22-19

Upgrade

Chardan Capital Markets

Neutral → Buy

$18

Nov-06-18

Upgrade

B. Riley FBR

Neutral → Buy

$13.50 → $21

Sep-13-18

Initiated

Citigroup

Buy

$27

Aug-15-18

Upgrade

H.C. Wainwright

Neutral → Buy

$21

Aug-09-18

Reiterated

Stifel

Buy

$18 → $20

Mar-28-18

Initiated

B. Riley FBR, Inc.

Neutral

$10

Mar-23-18

Downgrade

H.C. Wainwright

Buy → Neutral

$12

Mar-09-18

Initiated

Chardan Capital Markets

Neutral

Feb-05-18

Initiated

SunTrust

Buy

$13

Jan-16-18

Initiated

Evercore ISI

Outperform

$14

Nov-03-17

Reiterated

H.C. Wainwright

Buy

$6 → $10

May-23-17

Resumed

H.C. Wainwright

Buy

Apr-10-17

Reiterated

H.C. Wainwright

Buy

$8 → $5

Jan-31-17

Resumed

Leerink Partners

Mkt Perform

Dec-12-16

Initiated

H.C. Wainwright

Buy

Jul-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-18-20 07:30AM	Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria Business Wire +5.45%
Jun-15-20 08:49AM	Hedge Funds Arent Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore Insider Monkey +7.78%
Jun-12-20 08:31AM	2 Top Small-Cap Stocks to Buy Right Now Motley Fool
Jun-08-20 03:24AM	Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick SmarterAnalyst
Jun-05-20 09:40AM	Edited Transcript of DRNA earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-26-20 04:05PM	Dicerna to Participate in Jefferies Virtual Global Healthcare Conference Business Wire -5.84%
May-18-20 06:29AM	Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Analysts Are Way More Bearish Than They Used To Be Simply Wall St. +8.49%
May-12-20 04:05PM	Dicerna to Present at Upcoming May Investor Conferences Business Wire
May-10-20 10:39PM	Were Hedge Funds Right About Dicerna Pharmaceuticals Inc (DRNA)? Insider Monkey
09:23AM	Dicerna Pharmaceuticals, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next Simply Wall St.
May-09-20 04:31PM	Dicerna Pharmaceuticals Inc (DRNA) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 07:59AM	The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda Benzinga -8.80%
May-07-20 06:45PM	Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:05PM	Dicerna Announces First Quarter 2020 Financial Results and Provides a Business Update Business Wire
04:01PM	Dicerna Announces Appointment of Douglas Pagán as Chief Financial Officer Business Wire
02:59PM	11 Small-Cap Stocks Analysts Love the Most Kiplinger
May-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-30-20 04:05PM	Dicerna to Report First Quarter 2020 Financial Results on May 7, 2020 Business Wire -7.12%
Apr-29-20 07:36AM	We're Not Worried About Dicerna Pharmaceuticals's (NASDAQ:DRNA) Cash Burn Simply Wall St.
Apr-08-20 06:00AM	Biotech vet Gilman's startup earns $190M-plus in Roche deal American City Business Journals
Apr-06-20 06:26PM	Alnylam, Dicerna Join Forces to Take on Arrowhead GuruFocus.com +10.67%
10:30AM	Former gene-silencing rivals bury the hatchet with new partnership American City Business Journals
07:00AM	Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs Business Wire
Apr-01-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -5.66%
Mar-31-20 07:30AM	Dicerna Provides Initial Observations From PHYOX3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan Business Wire
Mar-26-20 04:05PM	Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic Business Wire
Mar-23-20 06:23PM	Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals Investor's Business Daily +10.61%
Mar-19-20 07:37AM	The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection Benzinga +17.62%
Mar-18-20 04:05PM	Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency Business Wire
Mar-09-20 01:25PM	Edited Transcript of DRNA earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -5.48%
Mar-02-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-29-20 08:53AM	Earnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Simply Wall St.
Feb-27-20 06:25PM	Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Dicerna Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Business Wire
Feb-20-20 04:05PM	Dicerna to Report Fourth Quarter and Full Year 2019 Financial Results on Feb. 27, 2020 Business Wire
Feb-18-20 04:05PM	Dicerna to Present at Upcoming Investor Conferences Business Wire
Feb-10-20 07:30AM	Dicerna Appoints Stephen Doberstein, Ph.D., to Board of Directors Business Wire +6.21%
Feb-03-20 04:30PM	Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-29-20 12:45PM	3 Charts Suggest Micro-Cap Stocks Are Headed Higher Investopedia
Jan-17-20 05:40PM	Pharma and Biotech Arent Worried About Democratic Candidates Attacks Against Drugmakers Barrons.com
Jan-02-20 04:30PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
08:10AM	Dow Jones Futures Signal Gains To Start 2020: Tesla Deliveries Loom; Google, Disney Test Key Support Investor's Business Daily
07:30AM	Dicerna Announces Closing of Agreement With Novo Nordisk for Discovery and Development of RNAi Therapies for Liver-Related Cardio-Metabolic Diseases Business Wire
Jan-01-20 07:40AM	We've made it to 2020. These are the top business issues to look for in the new year American City Business Journals
Dec-19-19 07:30AM	Dicerna Announces Closing of Worldwide Collaboration and Licensing Agreement With Roche for Treatments for Chronic Hepatitis B Virus Infection Business Wire
Dec-18-19 11:03AM	Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU Zacks
Dec-17-19 04:12PM	Biotech Succeeds With Gene-Silencing Drug But Its Stock Rally Fails Investor's Business Daily
07:30AM	Dicerna Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency Business Wire
06:00AM	Atlas, MPM, Partners funnel $49M into a new gene-silencing startup American City Business Journals
Dec-16-19 08:00AM	Alexion Exercises Option for Two Additional GalXC RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna Business Wire
Dec-15-19 08:46AM	The Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price Has Soared 805%, Delighting Many Shareholders Simply Wall St.
Dec-08-19 03:46PM	Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Dec-03-19 08:29AM	Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1% Zacks
Dec-02-19 04:30PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +10.06%
Nov-26-19 04:05PM	Dicerna to Present at Evercore ISI 2nd Annual HealthCONx Conference Business Wire
Nov-25-19 04:21PM	Edited Transcript of DRNA earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents +5.51%
Nov-19-19 07:56AM	The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga +12.20%
Nov-18-19 06:00AM	Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases Business Wire +10.83%
Nov-15-19 12:30PM	Drug giant Roche acquires Lexington biotech for $390M American City Business Journals
Nov-13-19 04:05PM	Dicerna to Present at the Stifel 2019 Healthcare Conference Business Wire
Nov-07-19 04:05PM	Dicerna Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress Business Wire
Nov-04-19 07:30AM	Dicerna to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019 Business Wire
Nov-01-19 08:06PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
07:38AM	The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 06:30AM	Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B American City Business Journals
06:30AM	Dicerna Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection Business Wire
Oct-28-19 04:13PM	Is Dicerna Pharmaceuticals Inc (DRNA) A Good Stock To Buy? Insider Monkey
10:32AM	Dicerna Pharmaceuticals (DRNA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
Oct-01-19 04:30PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-25-19 09:02PM	Edited Transcript of DRNA earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
04:05PM	Dicerna to Present at Two Upcoming Investor Conferences Business Wire
Sep-19-19 04:05PM	Dicerna Appoints Patrick Gray to Board of Directors to Support Continued Growth Business Wire
Sep-16-19 07:58AM	How Should Investors Feel About Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO Pay? Simply Wall St.
Sep-04-19 04:05PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-03-19 04:05PM	Dicerna to Present at H.C. Wainwright 21st Annual Global Investment Conference Business Wire
03:20AM	3 Biopharma Stocks With Over 50% Upside TipRanks
Aug-28-19 03:16PM	Is Arrowhead Pharmaceuticals Inc (ARWR)s Recently Published U.S. Patent Application A Blockbuster? Insider Monkey
Aug-15-19 09:00AM	BioBoyScouts Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR) Insider Monkey
Aug-09-19 08:05PM	Dicerna Pharmaceuticals Inc (DRNA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 04:05PM	Dicerna Reports Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Aug-02-19 04:05PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-01-19 04:05PM	Dicerna to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019 Business Wire
Jul-31-19 01:48PM	Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-15-19 07:30AM	Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1 (PH1) Business Wire
Jul-07-19 11:19AM	5 Stocks With Over 20% Upside Potential, Say Top Analysts TipRanks
Jul-02-19 07:00AM	RNAi startup Dicerna developing new liver drug American City Business Journals -5.32%
07:00AM	Dicerna to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Business Wire
Jul-01-19 04:30PM	Dicerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-21-19 07:30AM	Dicerna Presents Additional Data from PHYOX1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2) Business Wire
Jun-20-19 07:30AM	Globally Recognized Nephrologist Joins Dicerna to Support Continued Development of DCR-PHXC for the Treatment of Primary Hyperoxaluria Business Wire
Jun-18-19 11:45AM	Did The Underlying Business Drive Dicerna Pharmaceuticals's (NASDAQ:DRNA) Lovely 393% Share Price Gain? Simply Wall St.
Jun-13-19 07:30AM	Dicerna Hires Industry Veterans to Lead Regulatory Affairs and Patient Advocacy Business Wire
Jun-12-19 04:04PM	Bain's second life sciences fund comes in over $1 billion American City Business Journals +5.63%
Jun-11-19 06:57PM	Heres What Hedge Funds Think About Dicerna Pharmaceuticals Inc (DRNA) Insider Monkey
Jun-04-19 07:30AM	Dicerna Appoints Rob Ciappenelli Chief Commercial Officer Business Wire
Jun-03-19 04:30PM	Dicerna Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-28-19 04:05PM	Dicerna to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-16-19 07:30AM	Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus Business Wire

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brown Bob D	See Remarks	Jul 01	Option Exercise	3.42	8,185	27,993	13,185	Jul 06 09:01 PM
Weissman James B	Chief Operating Officer & EVP	Jul 01	Option Exercise	2.97	4,360	12,949	26,220	Jul 06 09:00 PM
Weissman James B	Chief Operating Officer & EVP	Jul 01	Sale	26.53	4,360	115,679	21,860	Jul 06 09:00 PM
Brown Bob D	See Remarks	Jul 01	Sale	26.50	8,185	216,929	5,000	Jul 06 09:01 PM
Brown Bob D	See Remarks	Jun 19	Option Exercise	2.97	9,670	28,720	14,670	Jun 23 08:01 PM
Brown Bob D	See Remarks	Jun 19	Sale	25.00	9,670	241,750	5,000	Jun 23 08:01 PM
Brown Bob D	See Remarks	Jun 01	Option Exercise	3.42	8,185	27,993	13,185	Jun 02 08:00 PM
Weissman James B	Chief Operating Officer & EVP	Jun 01	Option Exercise	2.97	4,360	12,949	26,220	Jun 02 08:02 PM
Weissman James B	Chief Operating Officer & EVP	Jun 01	Sale	21.06	4,360	91,807	21,860	Jun 02 08:02 PM
Brown Bob D	See Remarks	Jun 01	Sale	21.01	8,185	171,959	5,000	Jun 02 08:00 PM
Brown Bob D	See Remarks	May 11	Option Exercise	2.97	13,281	39,445	18,281	May 12 08:00 PM
Brown Bob D	See Remarks	May 11	Sale	24.00	13,281	318,744	5,000	May 12 08:00 PM
Brown Bob D	See Remarks	May 05	Option Exercise	3.42	8,185	27,993	13,185	May 07 08:01 PM
Brown Bob D	See Remarks	May 05	Sale	21.00	8,185	171,885	5,000	May 07 08:01 PM
Weissman James B	Chief Operating Officer & EVP	May 04	Option Exercise	2.97	4,360	12,949	26,220	May 06 08:00 PM
Weissman James B	Chief Operating Officer & EVP	May 04	Sale	20.20	4,360	88,072	21,860	May 06 08:00 PM
Brown Bob D	See Remarks	Apr 20	Option Exercise	2.97	13,281	39,445	18,281	Apr 21 08:01 PM
GREEN JOHN B	Chief Financial Officer	Apr 20	Option Exercise	5.45	25,624	139,651	45,045	Apr 22 08:00 PM
GREEN JOHN B	Chief Financial Officer	Apr 20	Sale	22.95	25,624	588,071	19,421	Apr 22 08:00 PM
Brown Bob D	See Remarks	Apr 20	Sale	23.00	13,281	305,463	5,000	Apr 21 08:01 PM
Brown Bob D	See Remarks	Apr 17	Option Exercise	3.42	8,185	27,993	13,185	Apr 21 08:01 PM
Brown Bob D	See Remarks	Apr 17	Sale	21.18	8,185	173,358	5,000	Apr 21 08:01 PM
Weissman James B	Chief Operating Officer & EVP	Apr 13	Option Exercise	2.97	4,360	12,949	26,220	Apr 14 08:33 PM
Weissman James B	Chief Operating Officer & EVP	Apr 13	Sale	20.20	4,360	88,072	21,860	Apr 14 08:33 PM
GREEN JOHN B	Chief Financial Officer	Apr 07	Option Exercise	3.88	20,469	79,395	39,890	Apr 09 08:13 PM
GREEN JOHN B	Chief Financial Officer	Apr 07	Sale	19.95	20,469	408,357	19,421	Apr 09 08:13 PM
Weissman James B	EVP & Chief Operating Officer	Mar 02	Option Exercise	2.97	4,360	12,949	26,220	Mar 03 08:30 PM
Brown Bob D	See Remarks	Mar 02	Option Exercise	3.42	8,185	27,993	13,185	Mar 03 08:31 PM
Brown Bob D	See Remarks	Mar 02	Sale	21.00	8,185	171,885	5,000	Mar 03 08:31 PM
Weissman James B	EVP & Chief Operating Officer	Mar 02	Sale	20.61	4,360	89,854	21,860	Mar 03 08:30 PM
Brown Bob D	See Remarks	Feb 10	Option Exercise	3.42	8,185	27,993	13,185	Feb 11 08:01 PM
Brown Bob D	See Remarks	Feb 10	Sale	21.00	8,185	171,885	5,000	Feb 11 08:01 PM
Weissman James B	EVP & Chief Operating Officer	Feb 03	Option Exercise	2.97	4,360	12,949	26,220	Feb 04 08:03 PM
Weissman James B	EVP & Chief Operating Officer	Feb 03	Sale	20.20	4,360	88,072	21,860	Feb 04 08:03 PM
GREEN JOHN B	Chief Financial Officer	Jan 17	Option Exercise	2.97	47,969	142,468	67,390	Jan 21 08:00 PM
GREEN JOHN B	Chief Financial Officer	Jan 17	Sale	21.27	47,969	1,020,164	19,421	Jan 21 08:00 PM
Weissman James B	EVP & Chief Operating Officer	Jan 02	Option Exercise	3.12	4,360	13,624	26,220	Jan 03 08:00 PM
Weissman James B	EVP & Chief Operating Officer	Jan 02	Sale	21.88	4,360	95,376	21,860	Jan 03 08:00 PM
Brown Bob D	See Remarks	Dec 31	Option Exercise	3.10	16,941	52,565	16,941	Dec 31 07:00 PM
Brown Bob D	See Remarks	Dec 31	Sale	22.00	11,941	262,702	5,000	Dec 31 07:00 PM
Brown Bob D	See Remarks	Dec 30	Option Exercise	3.25	13,136	42,697	22,806	Dec 31 07:00 PM
Brown Bob D	See Remarks	Dec 30	Sale	21.85	22,806	498,401	0	Dec 31 07:00 PM
ROSSKAMP RALF	Chief Medical Officer	Dec 26	Option Exercise	2.91	20,000	58,200	23,564	Dec 27 08:08 PM
ROSSKAMP RALF	Chief Medical Officer	Dec 26	Sale	22.69	20,000	453,764	3,564	Dec 27 08:08 PM
FAMBROUGH DOUGLAS	Chief Executive Officer	Dec 18	Option Exercise	3.42	80,000	273,600	92,300	Dec 19 08:54 PM
Weissman James B	EVP & Chief Operating Officer	Dec 18	Option Exercise	9.09	11,001	99,999	25,705	Dec 19 08:34 PM
FAMBROUGH DOUGLAS	Chief Executive Officer	Dec 18	Sale	25.87	80,000	2,069,586	12,300	Dec 19 08:54 PM
FAMBROUGH DOUGLAS	Chief Executive Officer	Dec 17	Sale	26.17	59,021	1,544,345	12,300	Dec 19 08:54 PM
GREEN JOHN B	Chief Financial Officer	Dec 11	Option Exercise	5.45	8,000	43,600	18,698	Dec 11 08:00 PM
Koppel Adam	Director	Dec 04	Sale	24.68	1,500,000	37,020,000	4,080,237	Dec 06 05:00 PM
Weissman James B	EVP & Chief Operating Officer	Dec 02	Option Exercise	2.97	20,000	59,400	34,704	Dec 03 08:00 PM
Weissman James B	EVP & Chief Operating Officer	Dec 02	Sale	26.00	20,000	520,000	14,704	Dec 03 08:00 PM
Kolchinsky Peter	Director	Dec 02	Sale	24.98	137,176	3,427,137	0	Dec 02 04:30 PM
Kolchinsky Peter	Director	Nov 29	Sale	24.22	138,000	3,341,725	137,176	Dec 02 04:30 PM
Kolchinsky Peter	Director	Nov 27	Sale	24.04	368,700	8,864,765	275,176	Dec 02 04:30 PM
Kolchinsky Peter	Director	Nov 26	Sale	23.59	239,700	5,653,444	643,876	Nov 26 05:23 PM
GREEN JOHN B	Chief Financial Officer	Nov 25	Option Exercise	5.45	12,500	68,125	23,198	Nov 27 08:00 PM
GREEN JOHN B	Chief Financial Officer	Nov 25	Sale	24.95	12,500	311,875	10,698	Nov 27 08:00 PM
Kolchinsky Peter	Director	Nov 25	Sale	24.06	361,200	8,689,677	883,576	Nov 26 05:23 PM
Kolchinsky Peter	Director	Nov 22	Sale	22.52	197,700	4,451,492	1,244,776	Nov 26 05:23 PM
Kolchinsky Peter	Director	Nov 21	Sale	22.98	351,505	8,076,952	1,442,476	Nov 21 05:02 PM
Kolchinsky Peter	Director	Nov 20	Sale	22.93	265,505	6,088,879	1,793,981	Nov 21 05:02 PM
Weissman James B	EVP & Chief Operating Officer	Nov 19	Option Exercise	3.42	20,000	68,400	34,704	Nov 20 08:02 PM
Kolchinsky Peter	Director	Nov 19	Sale	23.92	397,183	9,501,293	2,059,486	Nov 21 05:02 PM
Bain Capital Life Sciences Inv	10% Owner	Nov 19	Sale	22.03	1,750,000	38,552,500	5,580,237	Nov 21 04:26 PM
Weissman James B	EVP & Chief Operating Officer	Nov 19	Sale	24.00	20,000	480,000	14,704	Nov 20 08:02 PM
GREEN JOHN B	Chief Financial Officer	Nov 18	Option Exercise	5.45	12,500	68,125	23,198	Nov 20 08:00 PM
Weissman James B	EVP & Chief Operating Officer	Nov 18	Option Exercise	3.42	20,000	68,400	34,704	Nov 20 08:02 PM
Weissman James B	EVP & Chief Operating Officer	Nov 18	Sale	22.00	20,000	440,000	14,704	Nov 20 08:02 PM
GREEN JOHN B	Chief Financial Officer	Nov 18	Sale	21.05	12,500	263,125	10,698	Nov 20 08:00 PM
Weissman James B	EVP & Chief Operating Officer	Nov 14	Option Exercise	3.42	20,000	68,400	34,704	Nov 15 08:03 PM
Weissman James B	EVP & Chief Operating Officer	Nov 14	Sale	20.00	20,000	400,000	14,704	Nov 15 08:03 PM
GREEN JOHN B	Chief Financial Officer	Nov 14	Sale	20.00	3,562	71,240	10,698	Nov 15 08:01 PM
Weissman James B	EVP & Chief Operating Officer	Oct 31	Option Exercise	3.42	15,000	51,300	29,704	Nov 01 07:00 PM
GREEN JOHN B	Chief Financial Officer	Oct 31	Option Exercise	5.45	12,500	68,125	26,760	Nov 01 07:03 PM
GREEN JOHN B	Chief Financial Officer	Oct 31	Sale	18.00	12,500	225,000	14,260	Nov 01 07:03 PM
Weissman James B	EVP & Chief Operating Officer	Oct 31	Sale	18.00	15,000	270,000	14,704	Nov 01 07:00 PM
Weissman James B	EVP & Chief Operating Officer	Oct 18	Option Exercise	3.42	4,904	16,772	14,704	Oct 18 07:30 PM
Weissman James B	Chief Business Officer	Aug 23	Sale	13.07	14,680	191,832	9,800	Aug 23 08:31 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience